Similarly, Illuccix®, also called gallium (68Ga) gozetotide or gallium (68Ga) PSMA-11 was approved by the FDA in 2020 for PET imaging of prostate-specific membrane antigen (PSMA)-positive prostate cancer, in which this radiopharmaceutical combines the radionuclide 68Ga with a mimetic peptide, Glu-NH-CO-NH-Lys(Ahx)-HBED-CC, which allows for the PSMA-expressing tumor cells for specific imaging. Here, FOLH1 is linked to prostate cancer.